Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction According to a Secondary Database Analysis

Abstract Introduction Ritlecitinib, an oral, selective dual inhibitor of Janus kinase (JAK) 3 and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases, is approved for treating severe alopecia areata (AA) in patients aged ≥ 12 years in the USA. This study describes characterist...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Samantha K. Kurosky, Ashley S. Cha-Silva, Jenny Austin, Arash Mostaghimi, Chesahna Kindred, Genevieve Gauthier, Mojgan Sadrarhami, Peter Anderson, Benjamin Ungar
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Adis, Springer Healthcare 2026-05-01
Serie:	Dermatology and Therapy
Soggetti:	Alopecia areata Real-world data Ritlecitinib
Accesso online:	https://doi.org/10.1007/s13555-026-01773-3
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!